PortalPublikationenUpdate Breast Cancer 2020 Part 4 - Advanced Breast Cancer

Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer

Standard

Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer. / Tesch, Hans; Müller, Volkmar; Wöckel, Achim; Ettl, Johannes; Belleville, Erik; Schütz, Florian; Hartkopf, Andreas; Thill, Marc; Huober, Jens; Fasching, Peter A; Kolberg, Hans-Christian; Schulmeyer, Carla E; Welslau, Manfred; Overkamp, Friedrich; Fehm, Tanja N; Lux, Michael P; Schneeweiss, Andreas; Lüftner, Diana; Janni, Wolfgang.

in: GEBURTSH FRAUENHEILK, Jahrgang 80, Nr. 11, 11.2020, S. 1115-1122.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Tesch, H, Müller, V, Wöckel, A, Ettl, J, Belleville, E, Schütz, F, Hartkopf, A, Thill, M, Huober, J, Fasching, PA, Kolberg, H-C, Schulmeyer, CE, Welslau, M, Overkamp, F, Fehm, TN, Lux, MP, Schneeweiss, A, Lüftner, D & Janni, W 2020, 'Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer', GEBURTSH FRAUENHEILK, Jg. 80, Nr. 11, S. 1115-1122. https://doi.org/10.1055/a-1270-7481

APA

Tesch, H., Müller, V., Wöckel, A., Ettl, J., Belleville, E., Schütz, F., Hartkopf, A., Thill, M., Huober, J., Fasching, P. A., Kolberg, H-C., Schulmeyer, C. E., Welslau, M., Overkamp, F., Fehm, T. N., Lux, M. P., Schneeweiss, A., Lüftner, D., & Janni, W. (2020). Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer. GEBURTSH FRAUENHEILK, 80(11), 1115-1122. https://doi.org/10.1055/a-1270-7481

Vancouver

Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F et al. Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer. GEBURTSH FRAUENHEILK. 2020 Nov;80(11):1115-1122. https://doi.org/10.1055/a-1270-7481

Bibtex

@article{7b5648b4e1384d4f9ece6683ca35844c,
title = "Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer",
abstract = "Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a PIK3CA mutation. The treatment of patients with a BRCA1 or BRCA2 mutation has also been improved by the introduction of PARP inhibitors. Attempts are now being made increasingly to extend treatment indications based on molecular patterns, to identify other patients who could benefit from a treatment and to integrate the newly established treatment methods in existing therapy sequences. This review articles summarises the latest information in this connection.",
author = "Hans Tesch and Volkmar M{\"u}ller and Achim W{\"o}ckel and Johannes Ettl and Erik Belleville and Florian Sch{\"u}tz and Andreas Hartkopf and Marc Thill and Jens Huober and Fasching, {Peter A} and Hans-Christian Kolberg and Schulmeyer, {Carla E} and Manfred Welslau and Friedrich Overkamp and Fehm, {Tanja N} and Lux, {Michael P} and Andreas Schneeweiss and Diana L{\"u}ftner and Wolfgang Janni",
note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).",
year = "2020",
month = nov,
doi = "10.1055/a-1270-7481",
language = "English",
volume = "80",
pages = "1115--1122",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "11",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer

AU - Tesch, Hans

AU - Müller, Volkmar

AU - Wöckel, Achim

AU - Ettl, Johannes

AU - Belleville, Erik

AU - Schütz, Florian

AU - Hartkopf, Andreas

AU - Thill, Marc

AU - Huober, Jens

AU - Fasching, Peter A

AU - Kolberg, Hans-Christian

AU - Schulmeyer, Carla E

AU - Welslau, Manfred

AU - Overkamp, Friedrich

AU - Fehm, Tanja N

AU - Lux, Michael P

AU - Schneeweiss, Andreas

AU - Lüftner, Diana

AU - Janni, Wolfgang

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

PY - 2020/11

Y1 - 2020/11

N2 - Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a PIK3CA mutation. The treatment of patients with a BRCA1 or BRCA2 mutation has also been improved by the introduction of PARP inhibitors. Attempts are now being made increasingly to extend treatment indications based on molecular patterns, to identify other patients who could benefit from a treatment and to integrate the newly established treatment methods in existing therapy sequences. This review articles summarises the latest information in this connection.

AB - Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a PIK3CA mutation. The treatment of patients with a BRCA1 or BRCA2 mutation has also been improved by the introduction of PARP inhibitors. Attempts are now being made increasingly to extend treatment indications based on molecular patterns, to identify other patients who could benefit from a treatment and to integrate the newly established treatment methods in existing therapy sequences. This review articles summarises the latest information in this connection.

U2 - 10.1055/a-1270-7481

DO - 10.1055/a-1270-7481

M3 - SCORING: Journal article

C2 - 33173239

VL - 80

SP - 1115

EP - 1122

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 11

ER -